Gesundheitskonzern: Fresenius baut seine Beteiligung an Fresenius Medical Care ab
Fresenius reduziert die Anteile an dem Dialyseversorger um fast drei Prozent. Der Erlös aus dem Verkauf von etwa acht Millionen Aktien fließt nicht nur in mehr Wachstum.
Bad Homburg – The healthcare conglomerate Fresenius is reducing its stake in the dialysis provider Fresenius Medical Care (FMC), the DAX giant announced on Thursday after the stock market's close. The company sold 7.8 million FMC shares, valued at approximately €300 million, representing about 2.9 percent of FMC's capital stock.
This reduces Fresenius' ownership from 27.8 to around 25 percent. The anticipated book profit of a low to medium two-digit million Euro range will be considered in the results of the Fresenius group for the third quarter of 2026. These remaining shares are subject to a restriction of up to 45 days. "With this step, we are creating additional space to invest capital strategically in our growth platforms," said Fresenius CEO Michael Sen. The proceeds will also be used to reduce debt.
While the Fresenius share rose by one percent in after-hours trading on the Tradegate trading platform, FMC's stock fell by nearly one percent. CEO Sen has been driving the restructuring of Fresenius since his appointment four years ago, with a focus on the operational subsidiaries Kabi and Helios.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
